ASIC1 and metastatic melanoma: The bioinformatic analysis confirmed this observation, as patients with metastatic melanoma and with lower expression of the ACCN2 gene demonstrate a better survival prognosis than patients with the elevated ACCN2 expression (Figure 11c).